Previous 10 | Next 10 |
NEW YORK, March 27, 2020 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against AnaptysBio, Inc. (“AnaptysBio” or the “Company”) (NASDAQ: ANAB) in the United States District Court for the Southern District o...
Biotech and biopharma stocks regained their footing last Friday after a historically brutal week. For instance, shares of AnaptysBio (NASDAQ: ANAB) closed up by 12.5% last Friday; bluebird bio (NASDAQ: BLUE) stock posted a modest 2.17% gain after dipping by as much ...
Shares of several biotech stocks were sinking on Thursday due to a major market sell-off related to increased worries about the impact of the coronavirus disease COVID-19. AnaptysBio (NASDAQ: ANAB) stock was down 8.2% as of 11:38 a.m. EDT after falling as much as 16.4% earlier in the day. Sh...
Quick Take Lyra Therapeutics ( LYRA ) has filed to raise $57.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is advancing a pipeline of treatment candidates for chronic rhinosinusitis patients. LYRA is in Phase 2 trials for its lead cand...
The three healthcare stocks AnaptysBio, Inc. (NASDAQ: ANAB) , Co-Diagnostics, Inc. (NASDAQ: CODX) , and Novavax, Inc. (NASDAQ: NVAX) are all taking it on the chin this dark and gloomy Monday. AnaptysBio's stock fell by as much as 13.4%, Co-Diagnostics' shares dipped by as much as ...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 02/13/2020. Please visit our Tracking Ole Andreas Halvorsen...
SAN DIEGO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of...
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen’s 13F stock portfolio on a quarterly basis. It is based on Viking Global’s regulatory 13F Form filed on 11/13/2019. Please visit our Tracking Ole Andreas Halvorsen...
JanOne (NASDAQ: JAN ) +127% on acquiring worldwide license for treatment of Peripheral Arterial Disease. More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Medicines Company, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States 60 Degrees Pharmaceuticals Inc. (SXTP) rose 98.3% to $0.4878 on volume of 116,444,604 shares NVIDIA Corporation (NVDA) fell 0.2% to $120.8 on volume of 26,900,560 shares Serve Robotics Inc. (SERV) rose 61.2% to $4.2399 on volume of 25...
2024-05-10 18:15:02 ET Wells Fargo analyst issues BUY recommendation for ANAB on May 10, 2024 05:01PM ET. The previous analyst recommendation was Buy. ANAB was trading at $23.41 at issue of the analyst recommendation. The overall analyst consensus : HOLD. Current ana...
Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024 Enrollment ongoing for global Phase 2b trial to treat rheumatoid arthritis (RA) and global Phase 2 trial to treat ulcerative colit...